236 related articles for article (PubMed ID: 30323610)
21. Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results.
Berman B; Goldenberg G; Hanke CW; Tyring SK; Werschler WP; Knudsen KM; Larsson T; Swanson N
J Drugs Dermatol; 2014 Jun; 13(6):741-7. PubMed ID: 24918567
[TBL] [Abstract][Full Text] [Related]
22. A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.
Tolley K; Kemmett D; Thybo S; Nasr R; Smethurst H
Eur J Health Econ; 2016 Apr; 17(3):287-304. PubMed ID: 25795391
[TBL] [Abstract][Full Text] [Related]
23. Ingenol mebutate gel for actinic keratosis.
Lebwohl M; Swanson N; Anderson LL; Melgaard A; Xu Z; Berman B
N Engl J Med; 2012 Mar; 366(11):1010-9. PubMed ID: 22417254
[TBL] [Abstract][Full Text] [Related]
24. A Prospective Pilot Clinical Trial to Evaluate the Efficacy and Safety of Topical Therapy with Ingenol Mebutate Gel 0.015% for Actinic Keratosis on an Expanded Area of the Chest.
Wu DC; Guiha I; Goldman MP
J Clin Aesthet Dermatol; 2017 Aug; 10(8):31-36. PubMed ID: 28979661
[No Abstract] [Full Text] [Related]
25. Field cancerization therapy with ingenol mebutate contributes to restoring skin-metabolism to normal-state in patients with actinic keratosis: a metabolomic analysis.
Righi V; Tarentini E; Mucci A; Reggiani C; Rossi MC; Ferrari F; Casari A; Magnoni C
Sci Rep; 2019 Aug; 9(1):11515. PubMed ID: 31395965
[TBL] [Abstract][Full Text] [Related]
26. Clinical Response to Ingenol Mebutate in Patients With Actinic Keratoses.
Batalla A; Flórez Á; Feal C; Peón G; Abalde MT; Salgado-Boquete L; de la Torre C
Actas Dermosifiliogr; 2015 Dec; 106(10):e55-61. PubMed ID: 26055975
[TBL] [Abstract][Full Text] [Related]
27. Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers.
Gupta AK; Paquet M
J Cutan Med Surg; 2013; 17(3):173-9. PubMed ID: 23673300
[TBL] [Abstract][Full Text] [Related]
28. Field Cancerization Therapies for Management of Actinic Keratosis: A Narrative Review.
Jetter N; Chandan N; Wang S; Tsoukas M
Am J Clin Dermatol; 2018 Aug; 19(4):543-557. PubMed ID: 29582369
[TBL] [Abstract][Full Text] [Related]
29. New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel.
Berman B
Clin Cosmet Investig Dermatol; 2012; 5():111-22. PubMed ID: 22956883
[TBL] [Abstract][Full Text] [Related]
30. Ingenol Mebutate Topical Gel A Status Report On Clinical Use Beyond Actinic Keratosis.
Del Rosso JQ
J Clin Aesthet Dermatol; 2016 Nov; 9(11 Suppl 1):S3-S11. PubMed ID: 28224020
[TBL] [Abstract][Full Text] [Related]
31. Noninvasive Long-term Monitoring of Actinic Keratosis and Field Cancerization Following Treatment with Ingenol Mebutate Gel 0.015.
Markowitz O; Wang K; Levine A; Schwartz M; Minhas S; Feldman E; Siegel DM
J Clin Aesthet Dermatol; 2017 Oct; 10(10):28-33. PubMed ID: 29344318
[No Abstract] [Full Text] [Related]
32. Actinic keratosis: rationale and management.
Dodds A; Chia A; Shumack S
Dermatol Ther (Heidelb); 2014 Jun; 4(1):11-31. PubMed ID: 24627245
[TBL] [Abstract][Full Text] [Related]
33. A randomized trial comparing simultaneous vs. sequential field treatment of actinic keratosis with ingenol mebutate on two separate areas of the head and body.
Pellacani G; Peris K; Guillen C; Clonier F; Larsson T; Venkata R; Puig S
J Eur Acad Dermatol Venereol; 2015 Nov; 29(11):2192-8. PubMed ID: 26300464
[TBL] [Abstract][Full Text] [Related]
34. Quality of life and side effects in patients with actinic keratosis treated with ingenol mebutate: a pilot study.
Jubert-Esteve E; Del Pozo-Hernando LJ; Izquierdo-Herce N; Bauzá-Alonso A; Martín-Santiago A; Jones-Caballero M
Actas Dermosifiliogr; 2015 Oct; 106(8):644-50. PubMed ID: 26130156
[TBL] [Abstract][Full Text] [Related]
35. Tolerability of Ingenol Mebutate Gel, 0.05%, for Treating Patients with Actinic Keratosis on the Scalp in a Community Dermatology Practice.
Bettencourt MS
J Clin Aesthet Dermatol; 2016 Mar; 9(3):20-4. PubMed ID: 27354884
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness and Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% and Imiquimod 5% in the Treatment of Actinic Keratosis in Spain.
Elías I; Ortega-Joaquín N; de la Cueva P; Del Pozo LJ; Moreno-Ramírez D; Boada A; Aguilar M; Mirada A; Mosquera E; Gibbons C; Oyagüez I
Actas Dermosifiliogr; 2016; 107(6):498-508. PubMed ID: 27130804
[TBL] [Abstract][Full Text] [Related]
37. Ingenol mebutate as topical treatment for actinic keratosis based on a prospective, non-interventional, multicentre study of real-life clinical practice in Germany: efficacy and quality of life.
Diepgen TL; Eicke C; Bastian M
Eur J Dermatol; 2019 Aug; 29(4):401-408. PubMed ID: 31625920
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of ingenol mebutate gel under maximum use conditions in large treatment areas.
Bucko AD; Jarratt M; Stough DB; Kyhl L; Villumsen J; Hall A
J Dermatolog Treat; 2018 Feb; 29(1):74-79. PubMed ID: 28524709
[TBL] [Abstract][Full Text] [Related]
39. Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy.
Neri L; Peris K; Longo C; Calvieri S; Frascione P; Parodi A; Eibenschuz L; Bottoni U; Pellacani G;
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):93-107. PubMed ID: 29920789
[TBL] [Abstract][Full Text] [Related]
40. Assessment of Efficacy and Irritation of Ingenol Mebutate Gel 0.015% Used With or Without Dimethicone Lotion for Treatment of Actinic Keratosis on the Face.
Jim On SC; Hashim PW; Nia JK; Lebwohl MG
J Drugs Dermatol; 2017 May; 16(5):432-436. PubMed ID: 28628678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]